SNY and SAN Related Headlines
Go Back- Press Release: Sanofi’s Board of Directors proposes the appointment of Christel Heydemann as an independent director
- Press Release: Filing of an amendment to the French “Document d’Enregistrement Universel” containing the Annual Financial Report
- Press Release: Sanofi and Regeneron’s Dupixent recommended for EU approval to treat chronic spontaneous urticaria in young children with ongoing symptoms despite treatment
- Press Release: Acoziborole Winthrop, developed by DNDi and Sanofi, receives CHMP positive opinion as three-tablet, single-dose treatment for most common form of sleeping sickness
- Sanofi announces leadership evolution in Specialty Care Business Unit
- Press Release: Sanofi's amlitelimab confirms its potential in atopic dermatitis
- Sanofi wins EU approval for Wayrilz to treat immune thrombocytopenia
- Press Release: Sanofi’s Wayrilz approved in the EU as the first BTK inhibitor to treat immune thrombocytopenia
- Press Release: Sanofi reaches agreement with the US government to lower medicine costs while strengthening innovation
- Dren Bio secures $100 million from Sanofi for B-cell therapy collaboration
- Dren Bio Expands Strategic Collaboration with Sanofi to Develop Next-Generation B-Cell Depletion Therapy
- Dupixent® (dupilumab) Approved as the First Targeted Medicine in the European Union (EU) in Over a Decade for Chronic Spontaneous Urticaria (CSU)
- Vida Ventures Marks Fourth Major Portfolio Acquisition in 2025, Capping a Record-Setting Year for Its Science-Led, Discipline-Driven Strategy
- Press release: Sanofi successfully prices USD 3 billion of bond issue
- UPDATE - Medidata Extends Collaboration with Sanofi for the Development of New Therapies with an Improved Patient Journey
- Press release: Q3: continued sales and earnings progress
- Sanofi's Tzield gets expedited FDA review for stage 3 type 1 diabetes
- Press Release: Sanofi’s Tzield accepted for expedited review in the US for stage 3 type 1 diabetes through FDA Commissioner's National Priority Voucher pilot program
- Press Release: Sanofi’s high-dose influenza vaccine demonstrates superior protection for older adults against hospitalization vs standard-dose
- EVOQ Therapeutics signs licensing deal with Sanofi worth over $500M
- EVOQ Therapeutics Announces Collaboration and License Agreement with Sanofi
- Revvity Announces Program to Revolutionize the Early Detection of Type 1 Diabetes
- Sanofi expands patient affordability program by offering access to all its insulins for $35 per month in the US
- Press Release: Update on the US regulatory review of tolebrutinib in non-relapsing, secondary progressive multiple sclerosis
- Mandy Moore and Celebrity Mom Squad join Sanofi to help protect babies from RSV with BEYFORTUS®
- Press Release: Sanofi’s Wayrilz approved in US as first BTK inhibitor for immune thrombocytopenia
- New Report Highlights Community Health Workers' Impact, Calls for Sustained Local Investment, During National CHW Awareness Week
- BEYFORTUS® reduced hospital and doctor visits for RSV disease in babies by 87%, according to largest US real-world study
- Sanofi awards Healthy Futures Solution Fund grants to advance community-led solutions, expand equitable access to care across Massachusetts
SNY and SAN Related Press Releases
Go Back- Press Release: Sanofi’s Board of Directors proposes the appointment of Christel Heydemann as an independent director
- Press Release: Filing of an amendment to the French “Document d’Enregistrement Universel” containing the Annual Financial Report
- Press Release: Sanofi and Regeneron’s Dupixent recommended for EU approval to treat chronic spontaneous urticaria in young children with ongoing symptoms despite treatment
- Press Release: Acoziborole Winthrop, developed by DNDi and Sanofi, receives CHMP positive opinion as three-tablet, single-dose treatment for most common form of sleeping sickness
- Sanofi announces leadership evolution in Specialty Care Business Unit
- Press Release: Sanofi's amlitelimab confirms its potential in atopic dermatitis
- Press Release: Sanofi’s Wayrilz approved in the EU as the first BTK inhibitor to treat immune thrombocytopenia
- Press Release: Sanofi reaches agreement with the US government to lower medicine costs while strengthening innovation
- Dren Bio Expands Strategic Collaboration with Sanofi to Develop Next-Generation B-Cell Depletion Therapy
- Dupixent® (dupilumab) Approved as the First Targeted Medicine in the European Union (EU) in Over a Decade for Chronic Spontaneous Urticaria (CSU)
- Vida Ventures Marks Fourth Major Portfolio Acquisition in 2025, Capping a Record-Setting Year for Its Science-Led, Discipline-Driven Strategy
- Press release: Sanofi successfully prices USD 3 billion of bond issue
- UPDATE - Medidata Extends Collaboration with Sanofi for the Development of New Therapies with an Improved Patient Journey
- Press release: Q3: continued sales and earnings progress
- Press Release: Sanofi’s Tzield accepted for expedited review in the US for stage 3 type 1 diabetes through FDA Commissioner's National Priority Voucher pilot program
- Press Release: Sanofi’s high-dose influenza vaccine demonstrates superior protection for older adults against hospitalization vs standard-dose
- EVOQ Therapeutics Announces Collaboration and License Agreement with Sanofi
- Revvity Announces Program to Revolutionize the Early Detection of Type 1 Diabetes
- Sanofi expands patient affordability program by offering access to all its insulins for $35 per month in the US
- Press Release: Update on the US regulatory review of tolebrutinib in non-relapsing, secondary progressive multiple sclerosis
- Mandy Moore and Celebrity Mom Squad join Sanofi to help protect babies from RSV with BEYFORTUS®
- Press Release: Sanofi’s Wayrilz approved in US as first BTK inhibitor for immune thrombocytopenia
- New Report Highlights Community Health Workers' Impact, Calls for Sustained Local Investment, During National CHW Awareness Week
- BEYFORTUS® reduced hospital and doctor visits for RSV disease in babies by 87%, according to largest US real-world study
- Sanofi awards Healthy Futures Solution Fund grants to advance community-led solutions, expand equitable access to care across Massachusetts
SNY and SAN Related SEC Filings
Go Back- Form 6-K Sanofi For: Mar 04
- Form 6-K Sanofi For: Mar 03
- Form 6-K Sanofi For: Feb 23
- Form SCHEDULE 13G/A Sanofi Filed by: Amundi
- Form S-8 Sanofi
- Form IRANNOTICE Sanofi
- Form 20-F Sanofi For: Dec 31
- Form 6-K Sanofi For: Feb 17
- Form 6-K Sanofi For: Feb 12
- Form 13F-HR Sanofi For: Dec 31
- Form 6-K Sanofi For: Feb 10
- Form 6-K Sanofi For: Feb 06
- Form S-8 POS Sanofi
- Form 6-K Sanofi For: Dec 31
- Form 6-K Sanofi For: Jan 23
- Form 6-K Sanofi For: Jan 16
- Form 6-K Sanofi For: Jan 09
- Form 6-K Sanofi For: Dec 29
- Form 6-K Sanofi For: Dec 29
- Form 6-K Sanofi For: Dec 29
- Form 6-K Sanofi For: Dec 23
- Form 6-K Sanofi For: Dec 22
- Form 6-K Sanofi For: Dec 15
- Form 6-K Sanofi For: Dec 12
- Form 6-K Sanofi For: Dec 03
- Form 6-K Sanofi For: Nov 18
- Form SCHEDULE 13G/A Sanofi Filed by: Amundi
- Form 13F-HR Sanofi For: Sep 30
- Form 6-K Sanofi For: Nov 03
- Form 6-K Sanofi For: Oct 31
- Form 424B5 Sanofi
- Form 6-K Sanofi For: Oct 28
- Form FWP Sanofi Filed by: Sanofi
- Form FWP Sanofi Filed by: Sanofi
- Form FWP Sanofi Filed by: Sanofi
- Form FWP Sanofi Filed by: Sanofi
- Form FWP Sanofi Filed by: Sanofi
- Form 424B5 Sanofi
- Form 6-K Sanofi For: Jun 30
- Form 6-K Sanofi For: Sep 30
- Form 6-K Sanofi For: Oct 24
- Form 6-K Sanofi For: Oct 15
- Form 6-K Sanofi For: Sep 26
- Form 6-K Sanofi For: Sep 22
- Form 6-K Sanofi For: Sep 17
- Form 6-K Sanofi For: Sep 04
- Form 6-K Sanofi For: Sep 03
- Form 6-K Sanofi For: Aug 29
- Form SCHEDULE 13G/A Sanofi Filed by: Amundi
- Form 6-K Sanofi For: Aug 07
- Form 6-K Sanofi For: Jun 30
- Form 6-K Sanofi For: Jun 30
- Form 6-K Sanofi For: Jul 31
- Form N-PX Sanofi For: Jun 30
- Form 13F-HR Sanofi For: Jun 30
- Form 6-K Sanofi For: Jul 22
- Form 6-K Sanofi For: Jul 18
- Form 6-K Sanofi For: Jul 02
- Form 11-K Sanofi For: Dec 31
- Form 11-K Sanofi For: Dec 31
- Form 6-K Sanofi For: Jun 24
- Form 6-K Sanofi For: Jun 18
- Form 6-K Sanofi For: Jun 17
- Form 6-K Sanofi For: Jun 06
